Targeting EGFR in colorectal cancer: beyond KRAS exon 2

Mené sur 999 patients atteints d'un cancer colorectal métastatique sans mutation de l'exon 2 du gène KRAS, cet essai international multicentrique de phase III compare l'efficacité, du point de vue de la survie globale, et la toxicité du panitumumab et du cetuximab

Résumé en anglais

In the past decade, the RAS—RAF oncogenic pathway has emerged as one of the key molecular pathways of both scientific and therapeutic interest in metastatic colorectal cancer. In particular, research has focused on elucidation of the role of mutations within the KRAS oncogene due to their association with lack of benefit from the anti-EGFR monoclonal antibodies cetuximab and panitumumab. Such lack of benefit was first shown in post-hoc molecular analyses of large phase 3 trials of these agents, an ...